Rabbit Monoclonal GuanylylCyclasebeta1 Antibody

Guanylyl cyclase beta 1 (GC-beta1), encoded by the *GUCY1B1* gene, is a critical subunit of the soluble guanylyl cyclase (sGC) enzyme. sGC, a heterodimeric protein composed of alpha (α1) and beta (β1) subunits, acts as a key receptor for nitric oxide (NO), mediating its vasodilatory and anti-proliferative effects by catalyzing the conversion of GTP to cyclic GMP (cGMP). This NO-sGC-cGMP signaling pathway is essential for regulating vascular tone, blood pressure, and cardiovascular homeostasis. Antibodies targeting GC-beta1 are vital tools for studying the expression, localization, and function of sGC in physiological and pathological contexts. They enable detection of protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into conditions such as hypertension, atherosclerosis, and pulmonary arterial hypertension. Dysregulation of sGC activity, including altered GC-beta1 expression or mutations, has been linked to endothelial dysfunction and cardiovascular diseases. Additionally, these antibodies help investigate post-translational modifications (e.g., oxidation or phosphorylation) that modulate sGC sensitivity to NO. As therapeutic strategies targeting sGC (e.g., sGC stimulators/activators) gain traction, GC-beta1 antibodies also support drug development by validating target engagement and mechanistic studies in preclinical models. Their specificity and reliability are crucial for advancing understanding of cGMP-mediated signaling in both vascular and non-vascular tissues.